Knight gets Canadian rights to Puma\'s Nerlynx

Knight gets Canadian rights to Puma's Nerlynx

14:40 EST 15 Jan 2019 | Elsevier Business Intelligence

Puma Biotechnology Inc. granted Knight Therapeutics Inc. exclusive rights to commercialize the breast cancer drug Nerlynx (ne...

Original Article: Knight gets Canadian rights to Puma's Nerlynx

More From BioPortfolio on "Knight gets Canadian rights to Puma's Nerlynx"